Journal: International Journal of Nanomedicine

Article Title: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

doi:

Figure Lengend Snippet: Approved and emerging liposome formulations

Article Snippet: DOXIL ® /Caelyx ® (doxorubicin) , SoyHPC/CHOL/DSPE-PEG , yes , Sequus Pharmaceuticals, 1997 , Kaposi’s sarcoma , Approved.

Techniques:

Journal: International Journal of Nanomedicine

Article Title: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

doi:

Figure Lengend Snippet: Targeted liposomes in advanced phase of trial

Article Snippet: DOXIL ® /Caelyx ® (doxorubicin) , SoyHPC/CHOL/DSPE-PEG , yes , Sequus Pharmaceuticals, 1997 , Kaposi’s sarcoma , Approved.

Techniques: Liposomes

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Preexisting antitumor immunity augments the antitumor effects of chemotherapy

doi: 10.1007/s00262-013-1417-7

Figure Lengend Snippet: T cell immunity is critical for the efficacy of chemotherapy on immunogenic tumors but not on non-immunogenic tumors. a Comparison of responses to cyclophosphamide (Cy) by small immunogenic MCA207 tumors in normal (WT) or T cell receptor beta gene (Tcrb) knockout mice. Ten-day tumors in normal mice or 8-day tumors in Tcrb knockout mice with similar size were treated with Cy once i.p. NoRx represents untreated controls. Tcrb knockout mice had a significantly decreased response to Cy than control WT mice (p < 0.05). One of two experiments is shown. b Comparison of responses by small MCA207 tumors to doxorubicin (Dox), gemcitabine (Gem) in normal (WT) and Tcrb knockout mice. Similar sized tumors were injected intratumorally with indicated drugs once. The untreated controls are same as in a. One of two experiments is shown. Tcrb knockout mice responded less to both intratumoral Dox and Gem than WT control mice (p < 0.05). c Response by small MCA207 tumors to Cy i.p. and Dox intratumorally in normal (WT) mice or mice depleted of T cells at the time of chemotherapy. Ten-day tumors were treated with indicated drugs once. T cells were depleted using CD4 and CD8 antibodies at the time of chemotherapy and repeated once 1 week later. WT mice did better and responded better to treatment with intratumoral Dox and i.p. Cy than mice treated with antibodies to CD4 and Cd8 to delete T cells (p < 0.05). One of three similar experiments is shown. d Responses by large MCA207 tumors to Cy i.p. in normal (WT) and Tcrb knockout mice. Tumors at different times of establishment from normal (WT) and Tcrb knockout mice, but with similar sizes were treated with Cy once i.p. One of two similar experiments is shown. Large tumors in wild-type (WT) control mice responded significantly better to Cy treatment than those from Tcrb knockout mice (p < 0.01). e Reponses of 7-day established non-immunogenic Pan02 tumors to Dox in normal mice or mice depleted of T cells. f Response of 12-day established non-immunogenic B16 tumors to Cy in normal mice or mice depleted of T cells. Responses were measured by tumor size (length × width), and presented as the mean ± SEM of tumor sizes of indicated number of mice in each group. These two non-immunogenic tumors failed to respond to chemotherapy

Article Snippet: Liposomal doxorubicin (DOXIL ® , Tibotec Therapeutics) was diluted to 1 mg/ml in PBS, and 0.1 ml volume was injected intratumorally (i.t.) (for large tumors) or para-tumorally (for small tumors).

Techniques: Comparison, Knock-Out, Control, Injection